Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A.B.-Field: Carboplatin + paclitaxel + bevacizumab + atezolizumab for non-squamous NSCLC with ILD
jRCTs041250206Phase 2Recruiting
- Sponsor
- National Hospital Organization
- Start
- Mar 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, paclitaxel, bevacizumab and atezolizumab in Non-small cell lung cancer (NS-NSCLC) and interstitial lung disease (ILD), sponsored by National Hospital Organization. Primary endpoint: 1-year survival rate. Started Mar 2026; status: recruiting.
02
Drugs
carboplatinpaclitaxelbevacizumabatezolizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)interstitial lung disease (ILD)
Beyond the preview
Go deeper on jRCTs041250206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250206.